SEC Form 4 · accession 0001179022-18-000026
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theodore Daniel Zucconi
Director
Period of report
Apr 16, 2018
Accepted (ET)
Apr 18, 2018 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 16, 2018 | M | 4,000 | $0.89 | A | 5,083 | D | |
| Common Stock | Apr 16, 2018 | S | 4,000 | $3.58 | D | 1,083 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $0.89 | Apr 16, 2018 | M | 4,000 | D | — | Dec 15, 2026 | Common stock | 4,000 | 27,250 | D |
Explanation of responses
- F1The options vested 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting.